7.10.2026 07:00:06 CEST | Thor Medical ASA | Non-regulatory press releases
Thor Medical, a leading supplier of high-purity isotopes to the
radiopharmaceutical industry, today announced that Norwegian Prime Minister
Jonas Gahr Støre will officially open the Company's AlphaOne production facility
at Herøya Industrial Park on October 19, 2026.
The opening was originally scheduled for September 9 but was postponed out of
respect for the occasion, as it coincided with the funeral of King Harald V.
Andrew Adamovich, Founder of AdvanCell, a leading clinical-stage
radiopharmaceutical company with operations across North America and Australia,
will also attend the opening and share his perspective on the rapidly growing
field of targeted alpha therapy and the critical role of reliable isotope supply
in bringing these therapies to patients at scale.
The opening ceremony will bring together guests from the radiopharmaceutical
industry, the Norwegian industrial and life science ecosystem, politics and
business. The ceremony is an invitation-only event. Members of the media wishing
to attend are asked to contact Mathias Nilsen Reierth at
mathias.reierth@thormedical.com for accreditation.
For further information, please contact:
Mathias Nilsen Reierth
Head of Communications and Corporate Affairs
+47 988 05 724
mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies.
Thor Medical's product portfolio includes lead-212 (Pb-212) and its precursor
isotopes thorium-228 (Th-228) and radium-224 (Ra-224). Based on naturally
occurring thorium, Thor Medical's production process requires neither
irradiation nor nuclear reactors, providing significant cost advantages while
minimizing radioactive waste.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by powering
the next generation of precision cancer treatment with high-purity isotopes.
Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange under the ticker symbol TRMED. For more information, visit
thormedical.com - http://thormedical.com.
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19094532/18581/Download%20announc
ement%20as%20PDF.pdf
.no/ir-files/17848634/19094532/18581/Download%20announc\
ement%20as%20PDF.pdf\